Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

Stock Information for Clearmind Medicine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearmind Medicine Inc.

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi?Billion?Dollar PTSD Therapeutics Market
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA?Regulated Phase I/II Trial
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.